Preferred Commer Stock Price, News & Analysis

Cellev8 Nutrition Inc. (OTC: CELV), formerly known as Preferred Commerce Inc., is a wellness and nutraceutical company focused on Superoxide Dismutase (SOD)-based supplements and cellular health. According to company statements, Cellev8 has positioned itself as a pioneer in delivering SOD in gummy form on a commercial scale, with a focus on antioxidant defense, cellular protection, metabolic health, and recovery.

The company describes itself as a biotechnology-driven nutrition business dedicated to advancing cellular health, antioxidant defense, and metabolic function through clinically validated, bioavailable formulations. Cellev8 is headquartered in Wellington, Florida, and its shares trade on the OTC market under the symbol CELV. The company emphasizes that its identity and mission are now centered on SOD-based wellness products, and it has clarified that earlier plans to enter the CBD/Cannabis sector never progressed beyond a non-binding letter of intent.

Business focus and core technology

Cellev8’s product strategy centers on SOD2, an enzymatic antioxidant the company highlights as a key defender against oxidative stress. Its formulations are described as using patent-pending delivery systems, including soluble fiber–enhanced gummies and proprietary transport mechanisms designed to protect SOD and other active ingredients through the digestive tract and improve absorption in the small intestine. Company communications state that this approach aims for near-complete delivery and enhanced bioavailability compared with typical antioxidant and vitamin products.

The company reports that it has filed two patents with the U.S. Patent and Trademark Office to protect its delivery systems, covering enhanced ingredient delivery, proprietary transport mechanisms, and applications across its product range. These systems are described as applicable to multiple formulations, including inflammation and recovery gummies, focus and memory products, and GLP‑1 support gummies.

Product lines and formulations

Based on the company’s disclosures, Cellev8’s product range includes several SOD‑centric gummies and related nutraceuticals:

• Inflammation & Recovery Gummies: Formulations that the company states are packed with SOD and other antioxidants, aimed at supporting cellular repair, reducing inflammation, and aiding recovery from physical exertion.
• Focus & Memory Gummies: Products described as formulated to enhance cognitive performance and mental clarity, with reported improvements in attention, memory recall, and processing speed in referenced studies of key ingredients.
• GLP‑1 Support / SlimCell™ Gummies: A gummy supplement branded as SlimCell™, presented as a post‑GLP‑1 support and weight management product. The formulation combines a special composition of SOD B® Dimpless, Morosil™, and clinically tested soluble fibers from corn. Company materials cite clinical data from suppliers indicating reductions in cellulite, waist and hip circumference, body mass index, and fat mass in trials of these ingredients.
• Sports nutrition formulations (Elev8™): An upcoming sports nutrition product described as leveraging the Melorun® SOD formulation, with referenced preclinical and clinical work around physical and mental wellbeing, oxidative stress, inflammation, and muscle and joint integrity.

Cellev8 also highlights a broader lineup of nutraceuticals under its brand, including formulations marketed for oxidative stress reduction, anti‑inflammatory effects, metabolic health, body composition support, and long‑term wellness. Across these offerings, the company repeatedly emphasizes its patent‑pending delivery mechanism, optimized release technology, and enhanced bioavailability as key differentiators.

Cellular health and antioxidant positioning

Company communications describe SOD as the body’s main enzymatic defense against oxidative stress and free radicals. Cellev8’s materials attribute a range of potential benefits to SOD‑based supplementation, including antioxidant effects, support for cellular repair, anti‑aging potential, cardiovascular and neuroprotective support, athletic recovery, and possible roles in reducing inflammation and oxidative damage. The firm also references the potential for SOD‑centered formulations to support mitochondrial function, energy production, detoxification processes, immune function, sleep quality, and long‑term cellular resilience.

The company states that its unique delivery system is designed to help active compounds bypass harsh gastric environments, reach target tissues more effectively, and maintain ingredient stability. This is presented as central to its goal of delivering clinically validated, bioavailable cellular health solutions and differentiating its products from conventional supplements.

Sports, performance, and professional adoption

Cellev8 places particular emphasis on sports and athletic performance. It reports that its products are used by professional and collegiate sports teams, with company updates citing adoption by dozens of teams across leagues such as the NFL, NBA, MLB, NHL, MLS, and NCAA in the U.S. and Canada. The company also highlights NSF and NSF Certified for Sport accreditation for its SOD‑based gummy, stating that it is the first supplement company to receive this certification for a product containing SOD. This certification is described as important for collegiate and professional athletes who require third‑party testing for banned substances and contaminants.

Partnerships and endorsements play a visible role in Cellev8’s positioning. The company has announced multi‑year collaborations and marketing relationships with figures and organizations in professional sports, including Pro Football Hall of Famer Andre Reed, and has referenced exposure at major sporting events such as the Super Bowl. It also notes advisory relationships with sports dietitians and functional medicine experts who work with professional teams and athletes.

Collaborations and distribution channels

Beyond sports teams, Cellev8 describes a network of collaborative agreements aimed at expanding distribution and market access. These include:

• A joint marketing venture with Vivos Therapeutics, Inc., combining Vivos’ FDA‑cleared oral devices for obstructive sleep apnea with Cellev8’s SOD2‑based gummies to address oxidative stress associated with sleep‑disordered breathing.
• A collaborative sales agreement with Zyppah, an anti‑snoring device company, targeting millions of consumers affected by snoring, with Cellev8’s Inflammation & Recovery Gummies positioned as a complement to Zyppah’s devices.
• Distribution through online retail channels such as Amazon, Vitacost, and Walmart online, as described by the company, as well as direct‑to‑consumer sales and influencer‑driven campaigns.

The company also references marketing relationships with agencies and ambassadors focused on retail velocity, social media, and outreach to professional and collegiate sports organizations. In shareholder communications, Cellev8 has indicated that it views licensing its delivery technology to larger nutraceutical or pharmaceutical companies as a potential future revenue stream.

Corporate evolution and identity

Cellev8 Nutrition Inc. has explicitly stated that it was formerly known as Preferred Commerce. It has clarified that earlier communications about entering the CBD/Cannabis industry did not result in finalized agreements or any purchase or sale of CBD or cannabis products. The company now presents its core identity as a SOD‑based supplement provider focused on cellular health, antioxidant defense, and wellness, and has applied to update its stock listing name to reflect this focus.

In its public statements, Cellev8 emphasizes a commitment to scientific research, clinical validation of key ingredients, and patent‑pending delivery methods. It presents itself as serving thousands of customers, including professional and collegiate athletic teams, and as aiming to expand its line of wellness products and distribution partnerships.

Risk and regulatory considerations

Company materials repeatedly include FDA disclaimers noting that statements about health benefits of its products have not been evaluated by the U.S. Food and Drug Administration and that its supplements are not intended to diagnose, treat, cure, or prevent any disease. Investors and consumers reviewing Cellev8 should consider that many of the benefits described are based on studies of individual ingredients, supplier data, and company‑reported outcomes, and that nutraceutical products are subject to different regulatory standards than prescription drugs.

FAQs about Cellev8 Nutrition Inc. (CELV)

The following frequently asked questions summarize information the company has provided in its public communications.